Zimmer Biomet Holdings, Inc. (ZBH) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 a...
Zimmer Biomet Holdings, Inc.'s revenue increased 7.2% year over year, from $7.68B to $8.23B.
Net income decreased 22.0% over the same period, from $903.8M to $705.1M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 7% in total.
Total debt increased by 29.8% to $6.93B.
The debt-to-equity ratio stands at 0.55, indicating a moderate leverage profile.
Operating cash flow grew 13.2% to $1.70B.
Zimmer Biomet Holdings, Inc. maintains a moderate net profit margin of 8.6%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $1.82B-6.1% | $249.1M | $1.29B | $279.5M | $395.7M | $21.72B | $4.74B | $12.37B |
| Q4 FY2024 | $2.02B+10.9% | $239.5M | $1.44B | $389.0M | $506.3M | $21.37B | $5.34B | $12.47B |
| Q1 FY2025 | $1.91B-5.6% | $182.0M | $1.36B | $292.3M | $382.8M | $22.18B | $6.58B | $12.40B |
| Q2 FY2025 | $2.08B+8.8% | $152.9M | $1.49B | $300.0M | $378.2M | $22.87B | $6.75B | $12.53B |
| Q3 FY2025 | $2.00B-3.7% | $230.9M | $1.44B | $351.3M | $418.7M | $23.49B | $7.51B | $12.76B |
| Q4 FY2025 | $2.24B+12.1% | $139.3M | $1.45B | $154.5M | $517.4M | $23.09B | $6.93B | $12.70B |
| Q1 FY2026 | $2.09B-7.0% | $238.1M | $1.51B | $373.2M | $359.4M | $22.72B | $7.59B | $12.68B |
| Q2 FY2026 | $2.18B+4.3% | $198.4M | $1.54B | $326.0M | $447.8M | $22.80B | $7.60B | $12.63B |
Balance Sheet Summary (Q2 FY2026)
Zimmer Biomet Holdings, Inc. (ZBH) Financial Statements & Revenue History
Zimmer Biomet Holdings, Inc. (ZBH) is a US-listed stock operating in the Healthcare sector, specifically the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry trading at $94.25 with a market capitalization of $18. This page provides 42 historical financial statements for Zimmer Biomet Holdings, Inc., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Zimmer Biomet Holdings, Inc. reported revenue of $8.2 billion, representing 7.2% year-over-year growth. The net profit margin of 8.6% indicates moderate profitability. The debt-to-equity ratio of 0.55 reflects moderate leverage.
ZBH Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Zimmer Biomet Holdings, Inc.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether ZBH is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track ZBH's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Zimmer Biomet Holdings, Inc. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of ZBH's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use ZBH Financial Data
Investors use Zimmer Biomet Holdings, Inc.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare ZBH's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how ZBH's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View ZBH's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Zimmer Biomet Holdings, Inc.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.ZBH trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.